Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, it offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. The company markets its products through internet, word of mouth, and sales force to pharmaceutical and biotechnology companies. Champions Oncology, Inc. was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. The company was incorporated in 1985 and is headquartered in Hackensack, New Jersey. more
Time Frame | CSBR | Sector | S&P500 |
---|---|---|---|
1-Week Return | 18.56% | -2.12% | -3% |
1-Month Return | 73.73% | -3.42% | -0.73% |
3-Month Return | 57.34% | -11.13% | 2.87% |
6-Month Return | 55.38% | -5.74% | 7.17% |
1-Year Return | 51.01% | 3.97% | 25.31% |
3-Year Return | -8.36% | 1.05% | 28.38% |
5-Year Return | 0.47% | 34.37% | 81.89% |
10-Year Return | 56.35% | 97.88% | 183.27% |
Apr '20 | Apr '21 | Apr '22 | Apr '23 | Apr '24 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 32.12M | 41.04M | 49.11M | 53.87M | 50.16M | [{"date":"2020-04-30","value":59.63,"profit":true},{"date":"2021-04-30","value":76.18,"profit":true},{"date":"2022-04-30","value":91.16,"profit":true},{"date":"2023-04-30","value":100,"profit":true},{"date":"2024-04-30","value":93.1,"profit":true}] |
Cost of Revenue | 16.88M | 21.47M | 23.63M | 29.53M | 29.40M | [{"date":"2020-04-30","value":57.17,"profit":true},{"date":"2021-04-30","value":72.71,"profit":true},{"date":"2022-04-30","value":80.02,"profit":true},{"date":"2023-04-30","value":100,"profit":true},{"date":"2024-04-30","value":99.56,"profit":true}] |
Gross Profit | 15.24M | 19.57M | 25.48M | 24.34M | 20.75M | [{"date":"2020-04-30","value":59.82,"profit":true},{"date":"2021-04-30","value":76.8,"profit":true},{"date":"2022-04-30","value":100,"profit":true},{"date":"2023-04-30","value":95.53,"profit":true},{"date":"2024-04-30","value":81.46,"profit":true}] |
Gross Margin | 47.45% | 47.68% | 51.88% | 45.18% | 41.38% | [{"date":"2020-04-30","value":91.46,"profit":true},{"date":"2021-04-30","value":91.9,"profit":true},{"date":"2022-04-30","value":100,"profit":true},{"date":"2023-04-30","value":87.09,"profit":true},{"date":"2024-04-30","value":79.76,"profit":true}] |
Operating Expenses | 16.71M | 19.23M | 24.87M | 28.79M | 28.11M | [{"date":"2020-04-30","value":58.04,"profit":true},{"date":"2021-04-30","value":66.79,"profit":true},{"date":"2022-04-30","value":86.39,"profit":true},{"date":"2023-04-30","value":100,"profit":true},{"date":"2024-04-30","value":97.65,"profit":true}] |
Operating Income | (1.47M) | 338.00K | 607.00K | (4.45M) | (7.36M) | [{"date":"2020-04-30","value":-241.85,"profit":false},{"date":"2021-04-30","value":55.68,"profit":true},{"date":"2022-04-30","value":100,"profit":true},{"date":"2023-04-30","value":-732.95,"profit":false},{"date":"2024-04-30","value":-1211.86,"profit":false}] |
Total Non-Operating Income/Expense | - | - | - | - | - | [{"date":"2020-04-30","value":"-","profit":true},{"date":"2021-04-30","value":"-","profit":true},{"date":"2022-04-30","value":"-","profit":true},{"date":"2023-04-30","value":"-","profit":true},{"date":"2024-04-30","value":"-","profit":true}] |
Pre-Tax Income | (1.84M) | 409.00K | 583.00K | (5.27M) | (7.31M) | [{"date":"2020-04-30","value":-316.47,"profit":false},{"date":"2021-04-30","value":70.15,"profit":true},{"date":"2022-04-30","value":100,"profit":true},{"date":"2023-04-30","value":-903.43,"profit":false},{"date":"2024-04-30","value":-1253.52,"profit":false}] |
Income Taxes | 130.00K | 75.00K | 35.00K | 68.00K | (32.00K) | [{"date":"2020-04-30","value":100,"profit":true},{"date":"2021-04-30","value":57.69,"profit":true},{"date":"2022-04-30","value":26.92,"profit":true},{"date":"2023-04-30","value":52.31,"profit":true},{"date":"2024-04-30","value":-24.62,"profit":false}] |
Income After Taxes | - | - | - | - | - | [{"date":"2020-04-30","value":"-","profit":true},{"date":"2021-04-30","value":"-","profit":true},{"date":"2022-04-30","value":"-","profit":true},{"date":"2023-04-30","value":"-","profit":true},{"date":"2024-04-30","value":"-","profit":true}] |
Income From Continuous Operations | (1.98M) | 334.00K | 548.00K | (5.33M) | (7.28M) | [{"date":"2020-04-30","value":-360.4,"profit":false},{"date":"2021-04-30","value":60.95,"profit":true},{"date":"2022-04-30","value":100,"profit":true},{"date":"2023-04-30","value":-973.54,"profit":false},{"date":"2024-04-30","value":-1327.74,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2020-04-30","value":"-","profit":true},{"date":"2021-04-30","value":"-","profit":true},{"date":"2022-04-30","value":"-","profit":true},{"date":"2023-04-30","value":"-","profit":true},{"date":"2024-04-30","value":"-","profit":true}] |
Net Income | (1.98M) | 362.00K | 548.00K | (5.33M) | (7.28M) | [{"date":"2020-04-30","value":-360.4,"profit":false},{"date":"2021-04-30","value":66.06,"profit":true},{"date":"2022-04-30","value":100,"profit":true},{"date":"2023-04-30","value":-973.54,"profit":false},{"date":"2024-04-30","value":-1327.74,"profit":false}] |
EPS (Diluted) | (0.14) | 0.02 | 0.03 | (0.39) | (0.49) | [{"date":"2020-04-30","value":-466.67,"profit":false},{"date":"2021-04-30","value":67,"profit":true},{"date":"2022-04-30","value":100,"profit":true},{"date":"2023-04-30","value":-1304,"profit":false},{"date":"2024-04-30","value":-1633.33,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
CSBR | |
---|---|
Cash Ratio | 0.15 |
Current Ratio | 0.75 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CSBR | |
---|---|
ROA (LTM) | -6.93% |
ROE (LTM) | -432.46% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CSBR | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.97 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.03 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CSBR | |
---|---|
Trailing PE | NM |
Forward PE | 22.88 |
P/S (TTM) | 2.00 |
P/B | 141.21 |
Price/FCF | NM |
EV/R | 1.87 |
EV/Ebitda | 69.91 |
PEG | NM |
Champions Oncology Inc (CSBR) share price today is $7.505
Yes, Indians can buy shares of Champions Oncology Inc (CSBR) on Vested. To buy Champions Oncology Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CSBR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Champions Oncology Inc (CSBR) via the Vested app. You can start investing in Champions Oncology Inc (CSBR) with a minimum investment of $1.
You can invest in shares of Champions Oncology Inc (CSBR) via Vested in three simple steps:
The 52-week high price of Champions Oncology Inc (CSBR) is $7.85. The 52-week low price of Champions Oncology Inc (CSBR) is $3.6.
The price-to-earnings (P/E) ratio of Champions Oncology Inc (CSBR) is
The price-to-book (P/B) ratio of Champions Oncology Inc (CSBR) is 141.21
The dividend yield of Champions Oncology Inc (CSBR) is 0.00%
The market capitalization of Champions Oncology Inc (CSBR) is $103.43M
The stock symbol (or ticker) of Champions Oncology Inc is CSBR